|
|
2400 Trade Centre Ave
Longmont, CO 80503 USA
phone:303-339-1410
fax:303.339.1411
|
|
| Symbol |
Private |
| Founded |
2002 |
| Employees |
15 |
|
|
| www.microphage.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Infectious disease diagnostics that are more sensitive and faster than currently used tests. |
|
| Management |
| Steve Lundy, Chief Executive Officer, Director; Alene Campbell, Chief Operations Officer; John H. Wheeler, VP, Business Development; J. Drew Smith, Research and Development Director; Michael Fiechtner, Director, Product Development; Scott Conlin, Marketing Director; Preston Brown, Manufacturing Director |
| |
|
|
| |
|
| Keywords |
| In vitro diagnostics, microphages |
|
|
|
| Description |
|
Microphage, Inc develops and markets infectious disease diagnostics that utilize it's bacteriophage virus technology. The diagnositcs include high performing, easy to use tests for the direct identification of Staphylococcus aureus (S. aureus) and rapid antibiotic testing of methicillin susceptible and resistant S. aureus (MSSA and MRSA). |
|
| Technology / Differentiation |
| MicroPhage's proprietary technology functions to identify specific bacteria - directly from samples and cultures of active infections. The platform technology also allows for analysis of direct antibiotic susceptibility and resistance testing. Microphage's technology enables significantly faster diagnosis, as compared to traditional bacterial culture assays, in conjunction with ncreased diagnostic sensitivity. |
|
| Market / Customers |
In a survey of Massachusetts physicians, diagnostic uncertainty ranked as one of the most serious obstactles for the appropriate and responsible prescribing of antibiotics, according to Tufts University's Alliance for the Prudent Use of Antibiotics (APUA). Point of care diagnostics are now accepted into all areas of medicine, from cardiac markers to glucose meters, but are consistently faulted with low sensitivity and specificity. MicroPhage diagnostics satisfy this demand with an easy to use point of care test capable of rapid, sensitive detection.
|
|
| Status |
| The first products are expected in late 2009 and useful for clinicians and hospital staff in methicillin-resitant Staphylococcus aureus (MRSA) identification and antibiotic testing. Additional bacterial pathogens that may be addressed with the company's technology include: Vancomycin-resistant Enterococcus (VRE), ESBL-producing Escherichia coli, drug resistant Pseudomonas aeruginosa, and penicillin-resistant Streptococcus pneumoniae. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members